SAGE Therapeutics, Inc. (SAGE)

59.58
0.31 0.52
NASDAQ
Prev Close 59.89
Open 59.91
Day Low/High 59.15 / 61.34
52 Wk Low/High 25.01 / 155.33
Volume 266.40K
Exchange NASDAQ
Shares Outstanding 51.97B
Market Cap 3.16B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Biotech Goes From Goat to Hero

Several members in my new biotech basket have continued to make notable upside moves throughout the recent rally, including today. Winners include Acadia Pharmaceuticals (ACAD), Aerie Pharmaceuticals (AERI), Cempra (CEMP), Intrexon (XON), Portola Ph...

My Takeaways and Observations

I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here.  Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...

My Takeaways and Observations

Another volatile today that was oil price-centric. A 265-point intraday DJIA move, 30+ handles on the S&P and a 10-basis-point move in the 10-year U.S. note yield. A yawner! Classic rally from the lows, led by a reversal in crude oil, lower bond pri...

My Outlook for the Market's Major Sectors (Part Deux)

Here's the second part of my latest outlook for the market's major sectors. (You can read the first part here): Health Care/Biotech The political battle over health care intensified over the last few months as Democratic and Republican presidential ...

My Takeaways and Observations

It was a nice win for the bulls today. All the action was at the get go as the market flatlined after 10 a.m. ET. I am sorry, but I had little to say in my Diary as the market didn't talk back to me much. I end the day in market neutral, which is a ...

Takeaways and Observations

Hello, all -- I'm back! Great job yesterday by Chris "Not the Designer" Versace in subbing for me. My takeaways and observations regarding yesterday's action: St. Louis Fed President James Bullard is full of bull. Ray Dalio of hedge fund Bridgewater...

Biotech Breakout

Given my risk-averse profile, I made the unusual move last week of buying a basket of biotech stocks. And yesterday, I noted that Biotech Could Be Close to a 'Double Bottom': "I recently created a basket of a dozen speculative and conservative biote...

Biotech Goes From 'Zero' to 'Hero'

My basket of 12 biotech stocks is rocking this morning! We're seeing a 9% rally in Cempra (CEMP), a 5% rise in Intrexon (XON), a 4% gain in Acadia Pharmaceuticals (ACAD) and a 3% boost in Sage Therapeutics (SAGE).

Today's Takeaways and Observations

Chuck (Judge Smails) thoroughly embarrassed me into making a day's end post, noting that when I was younger I had the energy to still complete Takeaways. He went on to write that my current age is slowing me down. I know (hope!) you were kidding and...

Today's Takeaways and Observations

There was something for everyone (bulls and bears) today. Volatility cubed! My early perspective was outlined in "Drilling Teeth Without Novacain."  I bought the test and premarket weakness unemotionally as promised and expanded my net long exposure...

9 Rising Stocks in a Falling Market

Stocks are near the day's lows as I write this -- and an old traders' adage is to "buy what's green in a flow of red." That's not a strategy I plan to employ today. But for contrarians who are looking for some trades in a potential market turnaround...

Buying Biotechs

The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.